Greater persistence and adherence to basal insulin therapy is associated with lower healthcare utilization and medical costs in patients with type 2 diabetes: a retrospective database analysis

被引:0
|
作者
Aroda, Vanita R. [1 ]
Nielsen, Nick [2 ]
Mangla, Kamal K. [2 ]
Multani, Jasjit [3 ]
Divino, Victoria [3 ]
Namvar, Tarlan [4 ]
Rajpura, Jigar [4 ]
机构
[1] Brigham & Womens Hosp, Endocrinol Diabet & Hypertens, Boston, MA 02115 USA
[2] Novo Nord A S, Bagsvaerd, Denmark
[3] IQVIA Inc, Falls Church, VA USA
[4] Novo Nordisk Inc, Plainsboro, NJ USA
关键词
Patient Compliance; Health Care Costs; Diabetes Mellitus; Type; 2; ECONOMIC OUTCOMES; FOLLOW-UP; MELLITUS; PREDICTORS; MANAGEMENT; PEOPLE; IMPACT; PEN;
D O I
10.1136/bmjdrc-2023-003825
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction We aimed to assess persistence and adherence to basal insulin therapy, their association with all-cause healthcare resource utilization (HCRU) and direct medical costs, and predictors of persistence and adherence in adults with type 2 diabetes.Research design and methods A retrospective cohort study was conducted with US adults with type 2 diabetes initiating basal insulin therapy between January 1, 2016, and December 31, 2018, using IQVIA PharMetrics Plus claims data. Persistence and adherence were assessed during 1 year post-initiation per previous definitions. Demographic/clinical characteristics were assessed during the 1 year pre-initiation. Inverse probability of treatment weighting (IPTW) was used to adjust for confounding variables. Post-IPTW, all-cause HCRU and direct medical costs were assessed during the first-year and second-year post-initiation by persistence and adherence status. Multivariable logistic regression was used to identify predictors of persistence and adherence.Results The final sample comprised 64,953 patients; 56.8% demonstrated persistence and 41.9% demonstrated adherence. Patients demonstrating persistence and adherence were significantly less likely to have a hospitalization than patients demonstrating non-persistence or non-adherence, respectively. In the second-year post-initiation, total mean all-cause direct medical costs per patient were lower for patients demonstrating persistence and significantly lower for patients demonstrating adherence. Prior use of both oral and injectable antidiabetic medication predicted persistence and adherence compared with patients with only prior oral antidiabetic medication use (persistence OR, 1.50 (95% CI, 1.44 to 1.57); adherence OR, 1.48 (95% CI, 1.42 to 1.55)).Conclusions Persistence and adherence to basal insulin was associated with fewer hospitalizations and lower direct medical costs.
引用
收藏
页数:12
相关论文
共 50 条
  • [31] Fracture risk and healthcare resource utilization and costs among osteoporosis patients with type 2 diabetes mellitus and without diabetes mellitus in Japan: retrospective analysis of a hospital claims database
    Masayo Sato
    Wenyu Ye
    Tomoko Sugihara
    Yoshitaka Isaka
    BMC Musculoskeletal Disorders, 17
  • [32] Basal Insulin Persistence, Associated Factors, and Outcomes After Treatment Initiation: A Retrospective Database Study Among People with Type 2 Diabetes Mellitus in Japan
    Hadjiyianni, Irene
    Desai, Urvi
    Suzuki, Shuichi
    Ivanova, Jasmina I.
    Cao, Dachuang
    Kirson, Noam Y.
    Chida, Dai
    Enloe, Caroline
    Birnbaum, Howard G.
    Perez-Nieves, Magaly
    DIABETES THERAPY, 2017, 8 (01) : 149 - 166
  • [33] Basal Insulin Persistence, Associated Factors, and Outcomes After Treatment Initiation: A Retrospective Database Study Among People with Type 2 Diabetes Mellitus in Japan
    Irene Hadjiyianni
    Urvi Desai
    Shuichi Suzuki
    Jasmina I. Ivanova
    Dachuang Cao
    Noam Y. Kirson
    Dai Chida
    Caroline Enloe
    Howard G. Birnbaum
    Magaly Perez-Nieves
    Diabetes Therapy, 2017, 8 : 149 - 166
  • [34] CLINICAL OUTCOMES OF CONCOMITANT THERAPY OF EXENATIDE TWICE DAILY AND BASAL INSULIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: A RETROSPECTIVE DATABASE ANALYSIS IN THE UNITED STATES
    Pawaskar, Manjiri
    Li, Qian
    Hoogwerf, Byron J.
    Reynolds, Matthew W.
    Lee, Lauren J.
    Fonseca, Vivian
    ENDOCRINE PRACTICE, 2012, 18 (05) : 700 - 711
  • [35] Patients' persistence and adherence with glaucoma therapy: A longitudinal retrospective database analysis of ophthalmic lipids
    Walt, J
    Kline, SEJ
    Carlson, A
    Trygstad, GJ
    Ravelo, A
    VALUE IN HEALTH, 2004, 7 (03) : 258 - 258
  • [36] Patients' persistence and adherence with glaucoma therapy: A longitudinal retrospective database analysis of opthalmic lipids
    Kline, S
    Walt, J
    Carlson, A
    Trygstad, G
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2004, 45 : U457 - U457
  • [37] Glycemic control after initiating basal insulin therapy in patients with type 2 diabetes: a primary care database analysis
    Kostev, Karel
    Dippel, Franz W.
    Rathmann, Wolfgang
    DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY, 2015, 8 : 45 - 48
  • [38] MEDICATION ADHERENCE AND MEDICAL COSTS ASSOCIATED WITH EXENATIDE BID VERSUS LIRAGLUTIDE: A RETROSPECTIVE DATABASE ANALYSIS
    Pelletier, E. M.
    Pawaskar, M.
    Chapman, R.
    VALUE IN HEALTH, 2012, 15 (04) : A179 - A180
  • [39] Healthcare costs and hospitalizations in US patients with type 2 diabetes and cardiovascular disease: A retrospective database study (OFFSET)
    Evans, Marc
    Chandramouli, Abhishek Shankar
    Faurby, Mads
    Matthiessen, Kasper Sommer
    Mogensen, Phillip Bredahl
    Verma, Subodh
    DIABETES OBESITY & METABOLISM, 2022, 24 (07): : 1300 - 1309
  • [40] Impact of time to basal insulin initiation on glycaemic control in type 2 diabetes patients: an electronic medical record database analysis
    Raccah, D.
    Lew, E.
    Guerci, B.
    Meyers, J. L.
    Ajmera, M.
    Davis, K. L.
    Bertolini, M.
    Blonde, L.
    DIABETOLOGIA, 2016, 59 : S441 - S441